Navigation Links
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Date:12/14/2008

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

In the approval, the FDA required that LUSEDRA be used only by persons trained in the administration of general anesthesia and that all patients should be continuously monitored by persons not involved in the conduct of the procedure.

On May 7, 2008, the FDA Advisory Committee on Anesthetic and Life Support Drugs voted 6 to 3 in favor (with one abstention) of approval of LUSEDRA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The committee recommended use of LUSEDRA by healthcare providers who are appropriately trained.

"We are pleased with the FDA's decision to approve Lusedra, as it provides a new option for monitored anesthesia care (MAC) sedation in adult patients," said Cynthia Schwalm, President, Eisai Inc. "With the approval of Lusedra, Eisai continues to fulfill its human health care mission to address the unmet needs of patients."

The FDA has recommended that LUSEDRA be classified as a controlled substance. A final scheduling decision is expected from the U.S. Drug Enforcement Administration (DEA) after publishing a proposed rule in the Federal Register and allowing for public comment. Once LUSEDRA receives final scheduling designation, the label will be amended.

About LUSEDRA(TM) (fospropofol disodium) Injection

LUSEDRA(TM) (fospropofol disodium) Injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol. LUSEDRA
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
4. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
5. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
6. FDA Approves First Hepatitis B Viral Load Test
7. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
10. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... UPPSALA, Sweden, and WILMINGTON, Mass., March 28 ... accurate assessment of translesion,pressure gradients when compared to ... published in the Journal of,Interventional Cardiology (2008; Vol. ... that although CPG measurements derived from both a,catheter ...
... of TRU-016, Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, ... Product ... that it has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary ...
Other Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... Association to raise funds,through in-store ,pin-up, campaign, ALEXANDRIA, ... announced that Kmart has reinforced its,commitment to ADA and ... National Strategic Partner (NSP). As a National Strategic,Partner, Kmart ... mission to,prevent and cure diabetes, and to improve the ...
... to have active are:,Anthony Leiserowitz ... New Haven, Conn. A growing number of Americans ... action, and 40% say that a presidential candidates position on ... a national survey conducted by Yale University, Gallup and the ...
... 1, 2007 - When a child is farsighted or ... bilateral amblyopia may develop. In contrast to single-eye amblyopia ... image to the brain, bilateral amblyopia affects both eyes ... the October issue of the American Journal of Ophthalmology, ...
... 1, 2007 Newer ultrasound and magnetic resonance ... diagnosing fibrosis (scarring) and cirrhosis of the liver, ... of the journal Clinical Gastroenterology and Hepatology. , ... techniques may reduce the need for biopsiesprocedures done ...
... chance of trouble down the road, study says , , MONDAY, Oct. ... of TV, turn it off now and save yourself a lot ... that suggests that the negative effects of lots of early TV ... age of 6. , The study doesn,t confirm that television is ...
... assess the stability of three aspects of sleep behavior ... of mortality in short sleep, long sleep and frequent ... the October 1 issue of the journal SLEEP. , ... the Finnish Institute of Occupational Health in Helsinki, Finland, ...
Other Medicine News:Health News:Kmart Steps Out to Fight Diabetes 2Health News:Kmart Steps Out to Fight Diabetes 3Health News:Americans consider global warming an urgent threat, according to poll 2Health News:Early treatment of children with bilateral amblyopia essential, according to multisite study 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 3Health News:Kids' TV Viewing Tied to Behavioral Problems 2Health News:Kids' TV Viewing Tied to Behavioral Problems 3Health News:Both short and long sleep is associated with increased mortality 2
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
... Tips offer a safe alternative to using ... for applications such as PCR(a), pipetting radioactive ... Tips are excellent for tissue culture, gel ... Tips prevent aerosol contaminants and liquids from ...
... 3000 combines a powerful motor with a ... nozzle rotates to three positions for maximum ... the nozzle release button on the top ... nozzle position. The wide-angle position is ideal ...
... Peroxidase stain is the gold standard ... better agreement with your technologists manual ... efficiency. ,True RBC morphology advances cell ... allows for the differentiation of various ...
Medicine Products: